65,437 trials
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136
Volume Loss in the Infraorbital Hollow Area
Primary: Responder Rate Based on Merz Infraorbital Hollow Assessment Scale (MIHAS) at Week 8 — 80.6; 87.4; 73.7; 1.9 percentage of subjects
Gastrointestinal Injury · Complicated Diverticulitis
Primary: Rate of Surgical Site Infection — 5 Participants
Non Communicable Diseases · HIV
Primary: Change in Percent of Participants With Dual HIV and Blood Pressure Control — 52; 60 percentage of participants
Depressive Disorder, Major
Primary: Depressive Symptoms — 7.5; 10.5 units on a scale
Lung Biopsy
Primary: the Rate of Pneumothorax — 42; 60; 184; 168 Participants
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Primary: Overall Response Rate — 5; 2; 3; 1 Participants
Opioid-use Disorder
Primary: Acceptability of Intervention — 4.82; 3.19 score on a scale — p=<.001
Small Bowel Disease
Primary: Collect Serious Adverse Events and Device Deficiencies to Demonstrate Safety of the Motorized Spiral Endoscope (PowerSpiral) in Daily Medical Practice. — 6; 1 participants
Breast Neoplasm · Breast Neoplasm, Male · Triple Negative Breast Cancer
Primary: Establish the Safety of the IRX-2 Regimen When Administered Pre-operatively in Early Stage Breast Cancer (ESBC) Patients — 0; 0 Participants
Adult ALL · Healthy
Primary: Knee Range of Motion — 69.1; 67.0; 66.4; 66.1 degrees
Submental Fat
Primary: Safety - Adverse Events Follow up — 1; 2; 3; 0 Participants
Multiple Sclerosis
Primary: Number of Participants Experiencing Adverse Events (AEs) — 668; 775; 776 Participants
Opioid Dependence · Chronic Pain
Primary: Number of Participants Screened Compared to Number of Eligible Participants to Determine Feasibility of Recruitment — 97; 62; 351 Participants
Primary Myelofibrosis · Post-Polycythemia Vera · Myelofibrosis
Primary: Spleen Volume Response Rate (RR) — 35.8; 6.0 Percentage of Participants — p=<0.0001